Ligand Pharmaceuticals Closes Acquisition of XOMA Royalty
Ligand Pharmaceuticals has finalized its takeover of XOMA Royalty Corporation, the companies confirmed Monday from Emeryville, Calif.
Ligand Pharmaceuticals Incorporated completed its acquisition of XOMA Royalty Corporation on Monday, July 14, 2026, the Emeryville, California-based royalty firm announced, marking the close of a deal that had been previously disclosed by both companies.
XOMA Royalty, which built its business around acquiring and managing pharmaceutical royalty interests, will now operate under the umbrella of Ligand, a Nasdaq-listed company that similarly focuses on royalty and licensing assets in the biopharmaceutical space. The combination positions Ligand to expand its royalty portfolio and potentially capture a broader share of milestone and royalty payments tied to drug commercialization.
Read more BlackRock's GIP to Acquire Majority Stake in Summit Ridge Energy →
The closing represents a significant consolidation move in the pharmaceutical royalty sector, an industry that has drawn increasing investor attention as a lower-risk alternative to direct drug development. Royalty-focused firms collect payments tied to drug sales without bearing the full cost burden of clinical trials or manufacturing, making acquisitions like this one strategically attractive for companies seeking predictable revenue streams.
No additional financial terms or conditions of the closing were disclosed in Monday's announcement beyond confirmation that the transaction had been finalized. Ligand trades on the Nasdaq under the ticker symbol LGND.
Continue reading at GlobalNewswire.
